The Experts below are selected from a list of 5799 Experts worldwide ranked by ideXlab platform
Hesham Elhalawani - One of the best experts on this subject based on the ideXlab platform.
-
risk of Elevated Transaminases in non small cell lung cancer nsclc patients treated with erlotinib gefitinib and afatinib a meta analysis
Expert Review of Respiratory Medicine, 2016Co-Authors: Omar Abdelrahman, Hoda Ahmed, Hesham ElhalawaniAbstract:ABSTRACTThis meta-analysis has been conducted to determine the risk of Elevated Transaminases associated with the use of erlotinib, gefitinib and afatinib in patients with non-small cell lung cancer (NSCLC). Studies eligible for our analysis included randomized phase II and III trials of patients with NSCLC on the three agents which describe events of Elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Initial database search revealed 300 relevant citations. After excluding non-eligible studies, 24 trials were considered eligible for the analysis. The relative risk (RR) of all-grade Elevated ALT and AST was 1.82 (95% CI: 1.42–2.34; p < 0.00001) and 2.09 (95% CI: 1.54–2.83; p < 0.00001) respectively; while for high-grade Elevated ALT and AST, it was 9.23 (95% CI: 5.06–16.85; p < 0.00001) and 1.78 (95% CI: 0.5–6.26; p = 0.37), respectively. Our meta-analysis has shown that there is an overall Elevated risk of Elevated Transaminases with the use of these agents.
-
Risk of Elevated Transaminases in non-small cell lung cancer (NSCLC) patients treated with erlotinib, gefitinib and afatinib: a meta-analysis
Expert review of respiratory medicine, 2015Co-Authors: Omar Abdel-rahman, Hoda Ahmed, Hesham ElhalawaniAbstract:ABSTRACTThis meta-analysis has been conducted to determine the risk of Elevated Transaminases associated with the use of erlotinib, gefitinib and afatinib in patients with non-small cell lung cancer (NSCLC). Studies eligible for our analysis included randomized phase II and III trials of patients with NSCLC on the three agents which describe events of Elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Initial database search revealed 300 relevant citations. After excluding non-eligible studies, 24 trials were considered eligible for the analysis. The relative risk (RR) of all-grade Elevated ALT and AST was 1.82 (95% CI: 1.42–2.34; p
-
Risk of Elevated Transaminases in cancer patients treated with immune checkpoint inhibitors: a meta-analysis
Expert opinion on drug safety, 2015Co-Authors: Omar Abdel-rahman, Hesham Elhalawani, Mona FouadAbstract:Background: This meta-analysis has been conducted to determine the risk of Elevated Transaminases associated with immune checkpoint inhibitors use in patients with cancer.Methods: Studies eligible for our analysis included randomized Phase II and III trials of patients with cancer on ipilimumab, nivolumab, pembrolizumab, tremelimumab and pidilizumab, which describe events of Elevated Transaminases [alanine aminotransferase (ALT) and aspartate aminotransferase (AST)].Results: Initial database search revealed 210 relevant citations. After excluding noneligible studies, 10 trials were considered eligible for the quantitative synthesis. The RR of all-grade Elevated ALT and AST was 2.36 (95% CI 1.20–4.66; p = 0.01) and 1.53 (95% CI 0.73–3.22; p = 0.26), respectively, whereas for high-grade Elevated ALT and AST, it was 11.27 (95% CI 5.38–23.63; p < 0.0001) and 4.9 (95% CI 2.97–8.09; p < 0.0001), respectively.Conclusions: Our study has shown that the use of immune checkpoint inhibitors has a causal relationship ...
Xiaohua Chen - One of the best experts on this subject based on the ideXlab platform.
-
molecular epidemiology and clinical characteristics of hepatitis delta virus hdv infected patients with Elevated Transaminases in shanghai china
BMC Infectious Diseases, 2020Co-Authors: Yi Zhang, Yuyan Tang, Ting Yao, Zhenghao Tang, Guoqing Zang, Xiaohua ChenAbstract:Patients coinfected with HBV and hepatitis D virus (HDV) have a greater risk of HCC and cirrhosis. The current study was undertaken to assess HDV genotype distribution and determine clinical characteristics of hepatitis delta virus (HDV) among HBsAg positive individuals in Shanghai. This retrospective study involved 225 serum samples from HBsAg positive hospitalized patients from October 2010 to April 2013. HDV-specific RT-nested PCR was used to amplify HDV RNA. HDV genotypes were characterized by Next-generation sequencing (NGS), followed by phylogenetic analyses. HDV/HBV co-infected patients and HBV mono-infected patients were compared clinically and virologically. Out of the 225 HBsAg-positive serum samples with Elevated Transaminases, HDV-RNA was identified in 11 (4.9%) patients. The HBV loads in the HDV positive group were significantly lower than the HDV negative HBV-infected patients. The aminotransferase enzymes were significantly higher in HDV/HBV co-infected compared to HDV negative patients (P < 0.05). Phylogenetic analyses indicated that HDV-2 genotype being the predominant genotype, other HDV genotypes were not observed. HDV/HBV patients were significantly associated with a rather unfavourable clinical outcome. In summary, the prevalence of HDV infection in patients with Elevated Transaminases is not low and the predominance of HDV genotype 2 infection in Shanghai. This finding helps us to better understand the correlation of HDV/HBV co-infection. Moreover, Next-generation sequencing (NGS) technologies provide a rapid, precise method for generating HDV genomes to define infecting genotypes.
-
Molecular epidemiology and clinical characteristics of hepatitis delta virus (HDV) infected patients with Elevated Transaminases in Shanghai, China.
BMC infectious diseases, 2020Co-Authors: Yi Zhang, Yuyan Tang, Ting Yao, Zhenghao Tang, Guoqing Zang, Xiaohua ChenAbstract:Patients coinfected with HBV and hepatitis D virus (HDV) have a greater risk of HCC and cirrhosis. The current study was undertaken to assess HDV genotype distribution and determine clinical characteristics of hepatitis delta virus (HDV) among HBsAg positive individuals in Shanghai. This retrospective study involved 225 serum samples from HBsAg positive hospitalized patients from October 2010 to April 2013. HDV-specific RT-nested PCR was used to amplify HDV RNA. HDV genotypes were characterized by Next-generation sequencing (NGS), followed by phylogenetic analyses. HDV/HBV co-infected patients and HBV mono-infected patients were compared clinically and virologically. Out of the 225 HBsAg-positive serum samples with Elevated Transaminases, HDV-RNA was identified in 11 (4.9%) patients. The HBV loads in the HDV positive group were significantly lower than the HDV negative HBV-infected patients. The aminotransferase enzymes were significantly higher in HDV/HBV co-infected compared to HDV negative patients (P
-
Molecular epidemiology and clinical characteristics of hepatitis delta virus (HDV) infected patients with Elevated Transaminases in Shanghai, China
2020Co-Authors: Yi Zhang, Yuyan Tang, Ting Yao, Zhenghao Tang, Guoqing Zang, Xiaohua ChenAbstract:Abstract Background: Patients coinfected with HBV and hepatitis D virus (HDV) have a greater risk of HCC and cirrhosis. The current study was undertaken to assess HDV genotype distribution and determine clinical characteristics of hepatitis delta virus (HDV) among HBsAg positive individuals in Shanghai.Method: This retrospective study involved 225 serum samples from HBsAg positive hospitalized patients from October 2010 to April 2013. HDV-specific RT-nested PCR was used to amplify HDV RNA. HDV genotypes were characterized by Next-generation sequencing (NGS), followed by phylogenetic analyses. HDV/HBV co-infected patients and HBV mono-infected patients were compared clinically and virologically.Results: Out of the 225 HBsAg-positive serum samples with Elevated Transaminases, HDV-RNA was identified in 11 (4.9%) patients. The HBV loads in the HDV positive group were significantly lower than the HDV negative HBV-infected patients. The aminotransferase enzymes were significantly higher in HDV/HBV co-infected compared to HDV negative patients (P<0.05). Phylogenetic analyses indicated that HDV-2 genotype being the predominant genotype, other HDV genotypes were not observed. HDV/HBV patients were significantly associated with a rather unfavourable clinical outcome.Conclusion： In summary, our study showed that the prevalence of HDV infection in patients with Elevated Transaminases is not low and the predominance of HDV genotype 2 infection in Shanghai. This finding helps us to better understand the correlation of HDV/HBV co-infection. Moreover, Next-generation sequencing (NGS) technologies provide a rapid, precise method for generating HDV genomes to define infecting genotypes.
-
Molecular epidemiology and clinical characteristics of hepatitis delta virus (HDV) infected patients with Elevated Transaminases in Shanghai, China
2020Co-Authors: Yi Zhang, Yuyan Tang, Ting Yao, Zhenghao Tang, Guoqing Zang, Xiaohua ChenAbstract:Abstract Background: Patients coinfected with HBV and hepatitis D virus (HDV) have a greater risk of HCC and cirrhosis. The current study was undertaken to assess HDV genotype distribution and determine clinical characteristics of hepatitis delta virus (HDV) among HBsAg positive individuals in Shanghai.Method: This retrospective study involved 225 serum samples from HBsAg positive hospitalized patients from October 2010 to April 2013. HDV-specific RT-nested PCR was used to amplify HDV RNA. HDV genotypes were characterized by Next-generation sequencing (NGS), followed by phylogenetic analyses. HDV/HBV co-infected patients and HBV mono-infected patients were compared clinically and virologically.Results: Out of the 225 HBsAg-positive serum samples with Elevated Transaminases, HDV-RNA was identified in 11 (4.9%) HBsAg positive patients. The HBV loads in the HDV positive group were significantly lower than the HDV negative HBV-infected patients. The aminotransferase enzymes were significantly higher in HDV/HBV co-infected compared to HDV negative patients (P<0.05). Phylogenetic analyses indicated that HDV-2 genotype being the predominant genotype, other HDV genotypes were not observed. HDV/HBV patients were significantly associated with a rather unfavourable clinical outcomeConclusion： In summary, our study showed that the prevalence of HDV infection in patients with Elevated Transaminases is not low and the predominance of HDV genotype 2 infection in Shanghai. This finding helps us to better understand the correlation of HDV/HBV co-infection. Moreover, Next-generation sequencing (NGS) technologies provide a rapid, precise method for generating HDV genomes to define infecting genotypes.
Omar Abdel-rahman - One of the best experts on this subject based on the ideXlab platform.
-
Risk of Elevated Transaminases in non-small cell lung cancer (NSCLC) patients treated with erlotinib, gefitinib and afatinib: a meta-analysis
Expert review of respiratory medicine, 2015Co-Authors: Omar Abdel-rahman, Hoda Ahmed, Hesham ElhalawaniAbstract:ABSTRACTThis meta-analysis has been conducted to determine the risk of Elevated Transaminases associated with the use of erlotinib, gefitinib and afatinib in patients with non-small cell lung cancer (NSCLC). Studies eligible for our analysis included randomized phase II and III trials of patients with NSCLC on the three agents which describe events of Elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Initial database search revealed 300 relevant citations. After excluding non-eligible studies, 24 trials were considered eligible for the analysis. The relative risk (RR) of all-grade Elevated ALT and AST was 1.82 (95% CI: 1.42–2.34; p
-
Risk of Elevated Transaminases in cancer patients treated with immune checkpoint inhibitors: a meta-analysis
Expert opinion on drug safety, 2015Co-Authors: Omar Abdel-rahman, Hesham Elhalawani, Mona FouadAbstract:Background: This meta-analysis has been conducted to determine the risk of Elevated Transaminases associated with immune checkpoint inhibitors use in patients with cancer.Methods: Studies eligible for our analysis included randomized Phase II and III trials of patients with cancer on ipilimumab, nivolumab, pembrolizumab, tremelimumab and pidilizumab, which describe events of Elevated Transaminases [alanine aminotransferase (ALT) and aspartate aminotransferase (AST)].Results: Initial database search revealed 210 relevant citations. After excluding noneligible studies, 10 trials were considered eligible for the quantitative synthesis. The RR of all-grade Elevated ALT and AST was 2.36 (95% CI 1.20–4.66; p = 0.01) and 1.53 (95% CI 0.73–3.22; p = 0.26), respectively, whereas for high-grade Elevated ALT and AST, it was 11.27 (95% CI 5.38–23.63; p < 0.0001) and 4.9 (95% CI 2.97–8.09; p < 0.0001), respectively.Conclusions: Our study has shown that the use of immune checkpoint inhibitors has a causal relationship ...
Victor De Ledinghen - One of the best experts on this subject based on the ideXlab platform.
-
Diagnostic and predictive factors of significant liver fibrosis and minimal lesions in patients with persistent unexplained Elevated Transaminases. A prospective multicenter study
Journal of hepatology, 2006Co-Authors: Victor De Ledinghen, Vlad Ratziu, Xavier Causse, Brigitte Le Bail, Dominique Capron, Christophe Renou, Christophe Pilette, Valérie Oules, Eve Gelsi, Frédéric ObertiAbstract:Background/Aims In patients with unexplained Elevated Transaminases, prognosis of the liver disease and factors associated with increased risk of liver fibrosis and normal/subnormal liver are unknown. The aim of this prospective study was to identify diagnosis and clinical and biological factors associated with significant (bridging) fibrosis and minimal lesions of the liver in patients with persistent unexplained Elevated ALT levels. Methods From July 2002 through October 2004, all consecutive asymptomatic patients with unexplained chronically Elevated ALT levels were included. All patients had clinical, biological, ultrasonographic examination and a liver biopsy. Results 272 patients (60.3% males, mean age 46.4 years, BMI 26.7) were included. Pathological findings were: minimal lesions (18.7%), steatosis (26.8%), NASH (32.7%), and miscellaneous (21.7%). Significant fibrosis was found in 27.4% of cases, including 9 cases of cirrhosis. By multivariate analysis, independent predictors of significant fibrosis were tobacco use (OR 2.5, 95% CI 1.34–4.74 p =0.04), BMI>25 (2.49, 1.31–4.73 p =0.005) and diabetes (4.41, 1.73–11.29 p =0.002). Independent factors associated with minimal lesions were female gender (OR 3.4 95% CI 1.73–6.75 p p Conclusions In patients with unexplained chronically Elevated Transaminases, significant fibrosis is statistically associated with tobacco use, BMI>25 and diabetes, and minimal lesions are significantly associated with female gender and BMI
-
Should a liver biopsy be done in patients with subclinical chronically Elevated Transaminases
European journal of gastroenterology & hepatology, 2004Co-Authors: Victor De Ledinghen, Michel Combes, H. Trouette, Maria Winnock, Michel Amouretti, Antoine De Mascarel, Patrice CouzigouAbstract:In 10% of the patients with chronic abnormal alanine aminotransferase (ALT) levels no cause is found. The prognosis of this liver disease, the increased risk of liver fibrosis regardless of the types of histological lesions and the need for a liver biopsy are unknown. Nearly 50% of these cases are explained by non-alcoholic steatohepatitis (NASH). The aim of this study was to evaluate, in patients with accidentally detected chronically Elevated ALT levels, the prevalence of fibrosis and NASH, and the clinical and biological factors associated with each entity. Retrospectively, 67 patients (mean age, 46.6 +/- 12.1 years; 45 males) were included. All patients had a liver biopsy and were hepatitis B virus, hepatitis C virus, human immunodeficiency virus seronegative without alcohol, drug, autoimmune or genetically induced liver disease, with ALT > N (the upper limit of normal). NASH was evaluated according to necroinflammatory lesions and fibrosis. Fibrosis was evaluated according to the METAVIR score. Statistical analyses were performed using Student's t test, the Mann-Whitney rank-sum test and the chi-square test. Fibrosis scores were: F0, 37.3%; F1, 32.8%; F2, 26.9%; F3, 1.5%; and F4, 1.5%. NASH was absent in 59.7% and present in 40.3%. Significant differences were observed between F or = 2 fibrosis patients for aspartate aminotransferase (AST) and ALT and between patients with NASH or without for body mass index. Overall, the risk of F > or = 2 fibrosis was increased in patients with AST > N, ALT > 2N or AST > N and ALT > 2N. The prevalence of F > or = 2 fibrosis and NASH in patients with unexplained chronic abnormal ALT are 30% and 40%, respectively. Since the risk of F > or = 2 fibrosis is significantly increased in patients with AST > N and/or ALT > 2N, liver biopsy should be performed only in patients with AST > N or ALT > 2N.
Yi Zhang - One of the best experts on this subject based on the ideXlab platform.
-
molecular epidemiology and clinical characteristics of hepatitis delta virus hdv infected patients with Elevated Transaminases in shanghai china
BMC Infectious Diseases, 2020Co-Authors: Yi Zhang, Yuyan Tang, Ting Yao, Zhenghao Tang, Guoqing Zang, Xiaohua ChenAbstract:Patients coinfected with HBV and hepatitis D virus (HDV) have a greater risk of HCC and cirrhosis. The current study was undertaken to assess HDV genotype distribution and determine clinical characteristics of hepatitis delta virus (HDV) among HBsAg positive individuals in Shanghai. This retrospective study involved 225 serum samples from HBsAg positive hospitalized patients from October 2010 to April 2013. HDV-specific RT-nested PCR was used to amplify HDV RNA. HDV genotypes were characterized by Next-generation sequencing (NGS), followed by phylogenetic analyses. HDV/HBV co-infected patients and HBV mono-infected patients were compared clinically and virologically. Out of the 225 HBsAg-positive serum samples with Elevated Transaminases, HDV-RNA was identified in 11 (4.9%) patients. The HBV loads in the HDV positive group were significantly lower than the HDV negative HBV-infected patients. The aminotransferase enzymes were significantly higher in HDV/HBV co-infected compared to HDV negative patients (P < 0.05). Phylogenetic analyses indicated that HDV-2 genotype being the predominant genotype, other HDV genotypes were not observed. HDV/HBV patients were significantly associated with a rather unfavourable clinical outcome. In summary, the prevalence of HDV infection in patients with Elevated Transaminases is not low and the predominance of HDV genotype 2 infection in Shanghai. This finding helps us to better understand the correlation of HDV/HBV co-infection. Moreover, Next-generation sequencing (NGS) technologies provide a rapid, precise method for generating HDV genomes to define infecting genotypes.
-
Molecular epidemiology and clinical characteristics of hepatitis delta virus (HDV) infected patients with Elevated Transaminases in Shanghai, China.
BMC infectious diseases, 2020Co-Authors: Yi Zhang, Yuyan Tang, Ting Yao, Zhenghao Tang, Guoqing Zang, Xiaohua ChenAbstract:Patients coinfected with HBV and hepatitis D virus (HDV) have a greater risk of HCC and cirrhosis. The current study was undertaken to assess HDV genotype distribution and determine clinical characteristics of hepatitis delta virus (HDV) among HBsAg positive individuals in Shanghai. This retrospective study involved 225 serum samples from HBsAg positive hospitalized patients from October 2010 to April 2013. HDV-specific RT-nested PCR was used to amplify HDV RNA. HDV genotypes were characterized by Next-generation sequencing (NGS), followed by phylogenetic analyses. HDV/HBV co-infected patients and HBV mono-infected patients were compared clinically and virologically. Out of the 225 HBsAg-positive serum samples with Elevated Transaminases, HDV-RNA was identified in 11 (4.9%) patients. The HBV loads in the HDV positive group were significantly lower than the HDV negative HBV-infected patients. The aminotransferase enzymes were significantly higher in HDV/HBV co-infected compared to HDV negative patients (P
-
Molecular epidemiology and clinical characteristics of hepatitis delta virus (HDV) infected patients with Elevated Transaminases in Shanghai, China
2020Co-Authors: Yi Zhang, Yuyan Tang, Ting Yao, Zhenghao Tang, Guoqing Zang, Xiaohua ChenAbstract:Abstract Background: Patients coinfected with HBV and hepatitis D virus (HDV) have a greater risk of HCC and cirrhosis. The current study was undertaken to assess HDV genotype distribution and determine clinical characteristics of hepatitis delta virus (HDV) among HBsAg positive individuals in Shanghai.Method: This retrospective study involved 225 serum samples from HBsAg positive hospitalized patients from October 2010 to April 2013. HDV-specific RT-nested PCR was used to amplify HDV RNA. HDV genotypes were characterized by Next-generation sequencing (NGS), followed by phylogenetic analyses. HDV/HBV co-infected patients and HBV mono-infected patients were compared clinically and virologically.Results: Out of the 225 HBsAg-positive serum samples with Elevated Transaminases, HDV-RNA was identified in 11 (4.9%) patients. The HBV loads in the HDV positive group were significantly lower than the HDV negative HBV-infected patients. The aminotransferase enzymes were significantly higher in HDV/HBV co-infected compared to HDV negative patients (P<0.05). Phylogenetic analyses indicated that HDV-2 genotype being the predominant genotype, other HDV genotypes were not observed. HDV/HBV patients were significantly associated with a rather unfavourable clinical outcome.Conclusion： In summary, our study showed that the prevalence of HDV infection in patients with Elevated Transaminases is not low and the predominance of HDV genotype 2 infection in Shanghai. This finding helps us to better understand the correlation of HDV/HBV co-infection. Moreover, Next-generation sequencing (NGS) technologies provide a rapid, precise method for generating HDV genomes to define infecting genotypes.
-
Molecular epidemiology and clinical characteristics of hepatitis delta virus (HDV) infected patients with Elevated Transaminases in Shanghai, China
2020Co-Authors: Yi Zhang, Yuyan Tang, Ting Yao, Zhenghao Tang, Guoqing Zang, Xiaohua ChenAbstract:Abstract Background: Patients coinfected with HBV and hepatitis D virus (HDV) have a greater risk of HCC and cirrhosis. The current study was undertaken to assess HDV genotype distribution and determine clinical characteristics of hepatitis delta virus (HDV) among HBsAg positive individuals in Shanghai.Method: This retrospective study involved 225 serum samples from HBsAg positive hospitalized patients from October 2010 to April 2013. HDV-specific RT-nested PCR was used to amplify HDV RNA. HDV genotypes were characterized by Next-generation sequencing (NGS), followed by phylogenetic analyses. HDV/HBV co-infected patients and HBV mono-infected patients were compared clinically and virologically.Results: Out of the 225 HBsAg-positive serum samples with Elevated Transaminases, HDV-RNA was identified in 11 (4.9%) HBsAg positive patients. The HBV loads in the HDV positive group were significantly lower than the HDV negative HBV-infected patients. The aminotransferase enzymes were significantly higher in HDV/HBV co-infected compared to HDV negative patients (P<0.05). Phylogenetic analyses indicated that HDV-2 genotype being the predominant genotype, other HDV genotypes were not observed. HDV/HBV patients were significantly associated with a rather unfavourable clinical outcomeConclusion： In summary, our study showed that the prevalence of HDV infection in patients with Elevated Transaminases is not low and the predominance of HDV genotype 2 infection in Shanghai. This finding helps us to better understand the correlation of HDV/HBV co-infection. Moreover, Next-generation sequencing (NGS) technologies provide a rapid, precise method for generating HDV genomes to define infecting genotypes.